How GSK's new CEO lined up a major buyout to start his time at the top

SEC filings reveal how GSK's new CEO Luke Miels lined up the $10.6B Nuvalent buyout to land cancer drug neladalkib ahead of an FDA decision.

Raccontata daendpoints.news